News - Page 2 of 6 - Cristal Therapeutics

Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties

29th September 2020/in News /by Alex Jones

Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development CliCr® can be partnered or licensed as a stand-alone technology Cristal is actively seeking partners for CliCr® for a variety of applications Maastricht, The Netherlands, 29 September 2020 – Cristal Therapeutics, […]

Oncology Virtual Partnering

22nd September 2020/in Events /by Alex Jones

September 22-24 2020 Oncology Virtual Partnering Digital

BioPharm America

21st September 2020/in Events /by Alex Jones

September 21-24 2020 BioPharm America Digital

Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

2nd July 2020/in News /by Alex Jones

Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop and implement state-of-art (bio)analytical methodologies for further understanding of the biological behaviour of CriPec® nanomedicines Maastricht, The Netherlands, 2nd July 2020 – Cristal Therapeutics, a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer […]

Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

11th May 2020/in News /by Alex Jones

Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design Maastricht, The Netherlands, 11th May 2020 – Cristal Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces the publication of a paper on its CriPec® nanomedicine technology […]